Characteristic N (%) | 2000-2002 | 2003-2005 | 2006-2008 | 2009-2011 | Total | P* |
---|---|---|---|---|---|---|
Total | 1866 | 1849 | 1843 | 1767 | 3141 | |
Female sex | 598 (31.8) | 601 (32.3) | 544 (29.3) | 514 (28.4) | 932 (29.7) | 0.03 |
Race | ||||||
Black | 1136 (61.0) | 1088 (58.9) | 1047 (57.0) | 997 (56.4) | 1862 (59.3) | |
White | 591 (31.7) | 610 (33.0) | 596 (32.3) | 563 (31.9) | 962 (30.6) | |
Other | 142 (7.5) | 153 (8.2) | 202 (10.9) | 207 (11.7) | 317 (10.1) | <0.01 |
MSM | 566 (30.3) | 623 (33.6) | 640 (34.6) | 516 (29.2) | 889 (28.3) | <0.01 |
IDU | 261 (14.0) | 248 (13.4) | 208 (11.2) | 152 (8.6) | 340 (10.8) | <0.01 |
Age (years)† | 40 (34–46) | 42 (36–49) | 44 (37–51) | 46 (38–52) | 43 (36–50) | <0.01 |
CD4 cell count (cells/mm3) † | 376 (181–602) | 403 (218–621) | 440 (251–657) | 519 (335–737) | 440 (244–660) | <0.01 |
HIV RNA (log10 copies/ml) † | 2.92 (2.30-4.47) | 2.73 (BLD-4.45) | 2.05 (BLD-4.05) | BLD (BLD-2.58) | 2.37 (BLD-4.11) | <0.01 |
ART experience (person-years after ART exposure)‡ | 3322 (81.6) | 3505 (83.7) | 3680 (83.8) | 3871 (88.0) | 14378 (84.3) | <0.01 |